A view of the 23andMe headquarters in Sunnyvale, California, on March 25, 2025.
Tayfun Coskun | Anadolu | Getty Photos
Regeneron Pharmaceuticals on Monday introduced it’s going to purchase “considerably all” of 23andMe’s belongings for $256 million.
The drugmaker participated in a chapter public sale for 23andMe, a as soon as high-flying genetic testing firm that filed for for Chapter 11 chapter safety in March. Regeneron is shopping for 23andMe’s Private Genome Service, Complete Well being and Analysis Providers enterprise traces, in accordance with a release.
“We consider we can assist 23andMe ship and construct upon its mission to assist folks study their very own DNA and the best way to enhance their private well being, whereas furthering Regeneron’s efforts to enhance the well being and wellness of many,” Dr. George Yancopoulos, Regeneron’s president, stated in a press release.
Regeneron won’t purchase the corporate’s telehealth subsidiary, Lemonaid Well being, which 23andMe had acquired for round $400 million in 2021. Lemonaid Well being can be shut down, however Regeneron has supplied to make use of all staffers of the acquired enterprise models, in accordance with the discharge.
The deal continues to be topic to approval by the U.S. Chapter Courtroom for the Japanese District of Missouri. Pending approval, it is anticipated to shut within the third quarter of this yr, in accordance with the discharge.
23andMe rocketed into the mainstream due to its at-home DNA testing kits that gave clients perception into their household histories and genetic profiles. The five-time CNBC Disruptor 50 firm went public in 2021 by way of a merger with a particular objective acquisition firm. At its peak, 23andMe was valued at round $6 billion.
The corporate struggled to generate recurring income and get up viable analysis and therapeutics companies after going public, and it has been stricken by privateness issues since hackers accessed the information of almost 7 million clients in 2023.
In its chapter proceedings, 23andMe required all bidders to adjust to its privateness insurance policies, and a court-appointed, unbiased “Client Privateness Ombudsman” will assess the deal, the businesses stated.
A number of lawmakers and officers, together with the Federal Trade Commission, had expressed issues in regards to the security of customers’ genetic information by way of 23andMe’s sale course of. The privateness ombudsman will current a report on the acquisition to the court docket by June 10.
“We’re happy to have reached a transaction that maximizes the worth of the enterprise and allows the mission of 23andMe to reside on, whereas sustaining important protections round buyer privateness, selection and consent with respect to their genetic information,” Mark Jensen, 23andMe’s board chair, stated in a press release.
WATCH: Inside the fall of 23andMe
